Holen Sie sich die Stockscreener-App
71.35
0.88%
0.625
Handel nachbörslich:
71.35
Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten
Is Nektar Therapeutics (NKTR) Undervalued On Its Phase 3 Rezpegaldesleukin Launch? - simplywall.st
Nektar: Sanofi’s Exit Clears A Competitor But Raises The Bar In Atopic Dermatitis (NKTR) - Seeking Alpha
Nektar Therapeutics (NKTR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect - ACCESS Newswire
Nektar Therapeutics (NKTR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nektar Therapeutics (NKTR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NKTR|Nektar Therapeutics|Price:70.004|Chg%:-0.721 - TradingKey
Nektar Therapeutics (NKTR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Form 4 Nektar Therapeutics For: 24 July By Investing.com - Investing.com Nigeria
Nektar Therapeutics (NKTR) CEO granted 57,200 options with $15.15 strike - Stock Titan
Nektar Therapeutics Reports Vesting of 16,500 Stock Options for Chief R&D Officer Jonathan Zalevsky - Kalkine Media
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
How Investors Are Reacting To Nektar Therapeutics (NKTR) Launching Global Phase 3 ZENITH AD Trials - simplywall.st
ITH0.F interactive stock chart | Nektar Therapeutics R stock - Yahoo Finance UK
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nektar Therapeutics (NKTR) - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
NKTR|Nektar Therapeutics|Price:70.780|Chg%:+1.420 - TradingKey
Nektar Therapeutics Initiated at Buy by Canaccord Genuity - Moomoo
NKTR Up on Start of Phase III Program on Rezpeg for Atopic Dermatitis - Yahoo Finance
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Nektar (NKTR) Launches Global Trials for Novel Atopic Dermatitis Treatment - GuruFocus
Nektar Therapeutics Starts Phase 3 ZENITH AD Program Evaluating Rezpegaldesleukin in Moderate-to-Severe AD - The Dermatology Digest
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Enterprise value to EBIT forward of Nektar Therapeutics – BMV:NKTR - TradingView
Nektar Therapeutics (NKTR) Stock Looks Above Fair Value Despite Its 7x Run - simplywall.st
Enterprise value to EBITDA forward of Nektar Therapeutics – BMV:NKTR - TradingView
Price to sales forward of Nektar Therapeutics – BMV:NKTR - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Shareholders to Connect - ACCESS Newswire
ETFs Investing in Nektar Therapeutics Stocks - TradingView
Enterprise value to EBIT forward of Nektar Therapeutics – MUN:ITH0 - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Investors to Connect - ACCESS Newswire
2026-07-16 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Shareholders to Connect | NDAQ:NKTR | Press Release - Stockhouse
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Gr - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics - The National Law Review
BTIG Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $178 - 富途牛牛
Q32 bounces back to claim study success for alopecia drug - BioPharma Dive
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
2026-07-12 | Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Stockholders to Inquire about Securities Investigation | NDAQ:NKTR | Press Release - Stockhouse
Does Nektar Therapeutics (NKTR) Straddling Russell Growth and Value Indexes Reveal a Conflicted Narrative? - Sahm
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Enterprise value to EBITDA forward of Nektar Therapeutics – LSE:0UNL - TradingView
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Nektar Therapeutics (NKTR) - The Globe and Mail
Nektar Therapeutics (NKTR) Advances Autoimmune Pipeline, Is The Upside Already Priced In? - simplywall.st
NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema - Stocktwits
Insider Sell: Jonathan Zalevsky Sells Shares of Nektar Therapeutics (NKTR) - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Nektar Therapeutics R&D chief sells $397,670 of common stock - Investing.com
Nektar Therapeutics R&D chief sells $397,670 of common stock By Investing.com - Investing.com South Africa
Form 4 Nektar Therapeutics For: 2 July By Investing.com - Investing.com Nigeria
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):